IBD NC 2022
(O-1) Faecal biomarkers of neutrophil and eosinophil origin reflect response to biologics and corticosteroids in IBD
(O-2) Absolute and relative risks of kidney and urological complications in patients with inflammatory bowel disease
(O-3) Spondyloarthritis in first degree relatives of patients with inflammatory bowel disease: a nationwide cohort study
(O-4) Increased mortality in male Crohn’s disease patients after 30 years of follow-up (the IBSEN cohort).
(O-5) Endoscopic Recurrence or Anastomotic Wound Healing Phenomenon after Ileocolic Resection for Crohn’s Disease
(P-1) Long-term outcomes of vedolizumab in inflammatory bowel disease: the Swedish prospective multicentre SVEAH extension study
(P-2) Real-world outcomes of transitioning from intravenous to subcutaneous vedolizumab treatment: a SWIBREG cohort study
(P-3) Regional differences in biological and surgical IBD treatment in Norway 2011–2019
(P-4) Diagnosing Pediatric Inflammatory Bowel Disease Using Targeted Magnetic Nanoparticles
(P-5) Treatment patterns of Ulcerative Colitis and Crohn’s disease in the first year after diagnosis
(P-6) RXC008, a GI-targeted ROCK inhibitor, suppresses fibrosis and tissue injury in models of Crohn’s disease.
(P-7) Symptoms and symptom clusters in patients with IBD – results from The IBSEN III study
(P-8) Long-term real-world data of Ustekinumab in Ulcerative Colitis – the Stockholm Ustekinumab study – STOCUSTE
(P-9) Co-medication before and after onset of inflammatory bowel disease in adults or elderly
(P-10) Comparative study of a Point-of-care test and an enzyme-linked immunosorbent assay (ELISA) for infliximab levels
(P-11) Proof of concept study; Probiotic intervention in UC patients with insufficient response to anti-TNF treatment
(P-12) Is COVID-19 a trigger for steroid demanding disease activity in patients with inflammatory bowel disease?
(P-13) What matters to patients with inflammatory bowel disease in the encounter with healthcare professionals
(P-14) Optimized thiopurine therapy in patients with moderate-to-severe ulcerative colitis: Long-term follow up.
(P-15) Estimated glomerular filtration rate and the risk of inflammatory bowel disease in adults
(P-16) Harmful effects of an aldosterone synthase (CYP11B2) inhibitor (FAD286) on inflamed colon of the rat
(P-17) Varying incidence rates in lymphocytic and collagenous colitis indicate that they are two entities
(P-18) Genetics of Inflammatory bowel disease: Role of cytokine genes polymorphisms
(P-19) The vitamin D receptor in inflammatory bowel disease: no correlation to histologic or endoscopic inflammation